What's new?
2024
April 10, 2024
C4U and Sumitomo Pharma have entered into a license agreement, granting Sumitomo Pharma the right to develop and market regenerative medicine product for central nervous system diseases utilizing CRISPR-Cas3 technology.
C4U and Sumitomo Pharma have conducted three collaborative research projects since 2021, one of which resulted in the conclusion of this agreement.
April 3, 2024
The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” was issued by European Patent Office.
Patent registration number: No. 3636753
February 21, 2024
The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” was issued by Japan Patent Office.
Patent registration number: No. 7430358
February 14, 2024
The patent for the invention, “METHOD FOR PRODUCING KNOCK-IN CELL”, was issued by Japan Patent Office.
Patent registration number: No. 7426120
2023
December 14, 2023
December 7, 2023
The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD," was issued by the China National Intellectual Property Administration (CNIPA) on November 17, 2023.
Patent number is 110770342.
November 10, 2023
The patent for the invention, “METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN SAME," was issued by the United States Patent and Trademark Office on November 7, 2023.
Patent number is 11807869.
October 30, 2023
July 21, 2023
C4U and Rege Nephro have entered into a non-exclusive agreement, granting Rege Nephro the right to manufacture and sell cells induced to differentiate from PKD1 gene knockout induced pluripotent stem cells (iPS cells). Rege Nephro uses CRISPR-Cas3 technology to produce such PKD1 gene knockout iPS cells, and their product will be used for the discovery of new therapeutic agents to cure Autosomal Dominant (overt) Multiple Cystic Kidney Disease (ADPKD).
July 13, 2023
The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD," was issued by the Japan Patent Office on 23 June, 2023.
Patent registration number is 7301332.
This patent is matured from a divisional application of the Japanese Patent No. 6480647 issued in February 2019. Due to said patent, the claims and the scope of this patent become broader than the basic patent for the CRISPR-Cas3 system.
C4U anticipates that this patent will further strengthen the foundation of intellectual property rights with regard to CRISPR-Cas3 technology and further promote its application in a wide range of fields.
June 30, 2023
C4U has entered into a collaborative research and alliance agreement with Inplanta Innovations, Inc., the most capable and competent contract research company in the field of plant biotech in Japan, to promote a research and development for the application of CRISPR-Cas3 technology in the plant field.
C4U aims to widely deploy CRISPR-Cas3 genome editing technology as a platform technology, and this collaborative research and alliance agreement is an important part of that platform development.
Furthermore, C4U is looking forward to the possibility of contributing to social issues related to the global environment through the results of collaborative research and development with Inplanta Innovations in the future.
May 17, 2023
C4U Corporation has raised a total of 1.5 billion JPY (approximately $11 million at the then-effective exchange rate) for its Series B financing.
DCI Partners, Co., Ltd. who has been a lead investor since the Series A round in 2021, and other six investors including four new investors participated in this Series B round.
Since its establishment in March 2018, the accumulated funds have reached 2.6 billion JPY, and C4U plans to use the funds for further research and development of CRISPR-Cas3 system and its applications in a medical field, especially in vivo and ex vivo treatments.
In addition to the above, C4U is also seeking opportunities in any industrial fields.
March 15, 2023
Our researcher will give a poster presentation at the Keystone Symposia on Molecular and Cellular Biology "Precision Genome Engineering", in Whistler, Canada, from March 19-23, 2023.
2022
October 28, 2022
C4U and Brain Research Institute, Niigata University have entered into the collaborative research agreement for a novel gene therapy utilizing CRISPR -Cas3 technology.
September 1, 2022
The paper “Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3” was published in Nature Communications.
August 31, 2022
In addition to the current collaborative research and alliance agreement, C4U and Sumitomo Pharma identified additional target cells and genes for two regenerative medicine products respectively, and entered into a collaborative research and alliance agreement for each of them. These brought the total number of our collaborative research and alliance agreement between C4U and Sumitomo Pharma to three.
June 29, 2022
C4U and Logomix have entered into the joint research agreement on applying CRISPR-Cas3 genome editing technology to Logomix's Geno-WritingTM technology.
June 3, 2022
C4U and the Center for iPS Cell Research and Application(CiRA), Kyoto University have conducted a joint research since January 2020 to promote the research utilizing novel genome editing technology over iPS cells.
For the further expansion of this joint research, on May 30, 2022, C4U, CiRA and CiRA Foundation entered into a new collaborative research agreement for the purpose of the "research on genome editing for clinical iPS cells utilizing CRISPR-Cas3 technology".
February 2, 2022
The paper “CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus” was published in iScience.
For more details, please refer the release by the Institute of Medical Science, the University of Tokyo.
January 31, 2022
C4U and Sumitomo Dainippon Pharma have entered into the next stage of the joint research aiming the medical application of CRISPR-Cas3 by specifying the target gene and cell in the field of the central nervous system diseases. This progress has been made based on our joint research which was announced on August 3, 2021.
January 27, 2022
C4U, the Division of Animal Genetics, the Institute of Medical Science, the University of Tokyo and Transgenic Inc. have entered into the joint research agreement for genome editing experiments using mouse model with humanized exon.
January 11, 2022
C4U has been awarded the "JHVS2021 Venture Award" as a result of the "90-second elevator pitch" at the "Japan Healthcare Venture Summit 2021" held on October 13-15, 2021.
Our CEO Hirai will present the award-winning pitch at the JHVS 2021 Symposium to be held on February 3 and 4, 2022. (The pitch will be conducted in Japanese.)
2021
November 8, 2011
C4U and Nippon Gene have entered into a non-exclusive sublicense agreement granting Nippon Gene develop, manufacture and sell reagents utilizing CRISPR-Cas3 technology.
October 22, 2021
The patent for the invention, “A method for detecting specific DNA in the sample”, was issued by Japan Patent Office.
Patent registration number: No. 6940086
October 22, 2021
The patent for the invention, “GENOME EDITING METHOD”, was issued by Japan Patent Office.
Patent registration number: No. 6948718
October 13-15, 2021
C4U will participate in BIO JAPAN at PACIFICO Yokohama (JHVS booth V-44).
Our CEO Hirai will give a presentation at the pitch event on October 14, 2021 at 2pm.
October 7-8, 2021
C4U is participating in the 21st Annual Biotech in Europe Forum (BEF), a global bio-pharma industry partnering and investment event that will be held online on October 7-8, 2021.
September 28, 2021
C4U has entered into a non-exclusive sublicense agreement related to CRISPR-Cas3 technology with iPS Portal.
August 12, 2021
C4U and National Center for Child Health and Development have started the joint research on cell therapy for genetic diseases utilizing CRISPR-Cas3 technology.
August 4, 2021
C4U has raised $8.5 million (930 million yen) in Series A funding by the end of July.
August 3, 2021
C4U and Sumitomo Dainippon Pharma have entered into the joint research and alliance agreement aiming the medical application of CRISPR-Cas3.
July 21, 2021
C4U and Asahi Kasei have entered into the agreement for the joint research and development of a nucleic acid detection kit utilizing CRISPR-Cas3.
July 6, 2021
C4U have started a joint research on CRISPR-Cas3 delivery system using lipid nanoparticles with Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University.
July 5, 2021
C4U will be participating in BIO Asia-Taiwan 2021 Partnering event held online from July 21- 25, 2021
June 11, 2021
C4U and TAUNS Laboratories, Inc. have entered into the agreement for the joint development and commercialization of novel coronavirus SARS-CoV-2 diagnostics using CRISPR-Cas3 genome editing technology.
June 7, 2021
C4U is participating in BIO Digital 2021 Partnering event held online from June 10 - 18, 2021
2020
October 7, 2020
The Nobel Prize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna for the development of a method for genome editing that relates to CRISPR-Cas3 technology owned by C4U.
October 14-16, 2020
Participate BIO JAPAN at Yokohama Pacifico (JHVS booth V-51).
Please drop by our booth!
September 21, 2020
A novel CRISPR diagnostic, named "CONAN" method, developed by Prof. Tomoji Mashimo, was featured in the Asahi Shinbun.
August 11, 2020
Dr. Tomoji Mashimo and Mr. Akimitsu Hirai were added into the board members in the extraordinary meeting of shareholders, and Mr. Hirai was inaugurated as a president and CEO.
July 2, 2020
The paper was published in Human Genetics.
June 3, 2020
The paper was published in medrxiv.
May 25, 2020
C4U and Noile-Immune Biotech Partnership on PRIME Allogeneic CAR-T Cell Therapy Using CRISPR/Cas3 Genome Editing Technology
February 3, 2020
Akira Uotani has been appointed as the new CEO.
2019
December 6, 2019
The paper was published in nature communications.
October 9-11, 2019
Participate BIO JAPAN at Yokohama Pacifico (JHVS booth V-17).
Please drop by our booth!
C4U Corporation
Techno-Alliance Bldg. 7th floor, Osaka Univ. (OU),Yamadaoka 2-8, Suita, Osaka 565-0871 JAPAN
